Evidence map›Paper›PMID 36355511›Full record

ArticlePharmaceuticals (Basel, Switzerland)2022

Pyrazole-Based Thrombin Inhibitors with a Serine-Trapping Mechanism of Action: Synthesis and Biological Activity.

Calvin Dunker, Lukas Imberg, Alena I Siutkina, Catharina Erbacher, Constantin G Daniliuc, Uwe Karst, Dmitrii V Kalinin

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Calvin DunkerInstitute of Pharmaceutical and Medicinal Chemistry, University of Münster, 48149 Münster, Germany.
Lukas ImbergInstitute of Pharmaceutical and Medicinal Chemistry, University of Münster, 48149 Münster, Germany.
Alena I SiutkinaInstitute of Pharmaceutical and Medicinal Chemistry, University of Münster, 48149 Münster, Germany.
Catharina ErbacherInstitute of Inorganic and Analytical Chemistry, University of Münster, 48149 Münster, Germany.
Constantin G DaniliucInstitute for Organic Chemistry, University of Münster, 48149 Münster, Germany.ORCID 0000-0002-6709-3673
Uwe KarstInstitute of Inorganic and Analytical Chemistry, University of Münster, 48149 Münster, Germany.
Dmitrii V KalininInstitute of Pharmaceutical and Medicinal Chemistry, University of Münster, 48149 Münster, Germany.ORCID 0000-0003-2717-5364
University of Münster · DE

Funding

Deutsche Forschungsgemeinschaft KA 5558/1-1
6 · The paper itself

Abstract

New antithrombotic drugs are needed to combat thrombosis, a dangerous pathology that causes myocardial infarction and ischemic stroke. In this respect, thrombin (FIIa) represents an important drug target. We herein report the synthesis and biological activity of a series of 1

Indexed as

anticoagulantscovalent inhibitordabigatranpyrazolepyrazolo[1,5-a]quinazolin-5(4H)-onespyrazolo[5,1-b]quinazolin-9(4H)-onesthrombinthrombosisUllmann reaction

Identifiers

PMID36355511
PMCPMC9696832
OpenAlexW4307939601

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.